NCT01484067

Brief Summary

If a person qualifies to participate in this study, they will have an equal chance of being assigned to either of two groups. One group will receive a patch that they will need to carry with them, because as soon as a cold sore starts (within 1 hour) they will need to put the patch over the sore. The other group will not get a patch, but will need to follow the other instructions anyway. When a subject's outbreak begins, they will need to return to the study center within 24 hours. Then they will return according to the appointments given within 10 days. If the study staff sees that their sore has healed enough before 10 days, subjects will be told that they don't need to return again. As long as subjects are in the study, they will need to answer a few simple questions every day on a card or booklet called a diary, starting the first day of their outbreak. If a subject is assigned to the patch group, they must wear the patch all the time, taking it off only to replace it (if it gets loose, dirty, or unsightly) and at the study center, when they are asked to remove the patch so the sore can be checked. During the study subjects will be allowed to use paracetamol for pain, but no other treatments or medicine. If they use paracetamol, subjects must record it in their diary. The study will be stopped, and there will be no subject visits or treatments during the end of year holiday break. If a subject experiences an outbreak during the holiday, they may follow their usual treatment routine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
472

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2011

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

November 30, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 2, 2011

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

October 1, 2012

Status Verified

September 1, 2012

Enrollment Period

4 months

First QC Date

November 30, 2011

Last Update Submit

September 27, 2012

Conditions

Keywords

Herpes Simplex Virus

Outcome Measures

Primary Outcomes (5)

  • Overall Condition of Cold Sore

    Taking into account the size, physical impression of the lesion and overall quality of healing, clinician will score the overall condition of the cold sore on a scale of 0-10, where 0=Best and 10=Worst.

    Within 10 Days

  • Erythema

    Clinician's score on a scale of 0-10 for erythema, where 0=none and 10=most severe

    Within 10 Days

  • Edema

    Clinician's score on a scale of 0-10 for edema, where 0=none and 10=most severe

    Within 10 Days

  • Vesicles

    Clinician's score on a scale of 0-10 for vesicles, where 0=none and 10=most severe

    Within 10 Days

  • Scab/Crust

    Clinician's score on a scale of 0-10 for scab/crust, where 0=none and 10=most severe

    Within 10 Days

Secondary Outcomes (12)

  • Lesion Size

    Within 10 Days

  • Lesion Stage

    Within 10 Days

  • Pain

    Within 10 Days

  • Discomfort

    Within 10 Days

  • Itching

    Within 10 days

  • +7 more secondary outcomes

Study Arms (2)

Patch

EXPERIMENTAL

At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.

Device: Patch ( Compeed© Total CareTM Cold Sore Patch)

No Patch

NO INTERVENTION

No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.

Interventions

A cold sore patch containing zinc sulfate

Also known as: Compeed© Total CareTM Cold Sore Patch
Patch

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female or male 18-70 years old in good general health
  • Has a history of Herpes Labialis in the areas and with the frequency defined in the protocol.
  • Based on history, likely to experience a cold sore outbreak within next 2 to 3 months
  • Willing to provide informed consent
  • Willing to stop all other treatment of this condition and any topical products (lip balm, cosmetics, sunscreen) during test period
  • Women of child bearing potential must agree to use an adequate method of birth control (systemic birth control/intrauterine device)

You may not qualify if:

  • Self-reported to be pregnant, planning to become pregnant or nursing
  • Has any medical history or condition that might, per protocol or in the opinion of the investigator, compromise the subject's safety or the analysis of results.
  • Is taking or has taken within the 28 days before commencing treatment, protocol-specified medications or herbal supplements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Intertek CRS

Manchester, M15 6SE, United Kingdom

Location

MeSH Terms

Conditions

Herpes LabialisHerpes Simplex

Interventions

Transdermal Patch

Condition Hierarchy (Ancestors)

Herpesviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsSkin Diseases, ViralLip DiseasesMouth DiseasesStomatognathic DiseasesSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Equipment and Supplies

Study Officials

  • Clare Kendall

    Johnson & Johsnon Consumer and Personal Products Worldwide

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 30, 2011

First Posted

December 2, 2011

Study Start

November 1, 2011

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

October 1, 2012

Record last verified: 2012-09

Locations